Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Female sterilization

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,109 result(s) found for: Female sterilization. Displaying page 1 of 56.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2005-003319-64 Sponsor Protocol Number: S3B40042 Start Date*: 2007-07-05
    Sponsor Name:GlaxoSmithKline Research and Development Limited
    Full Title: A randomised, placebo-controlled, crossover study to measure the effect of alosetron on mucosal blood flow in female healthy volunteers and diarrhea-predominant IBS subjects
    Medical condition: Irritable Bowel Syndrome (IBS)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-005334-20 Sponsor Protocol Number: MO28047 Start Date*: 2012-02-23
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: A multicenter, open-label, single-arm study of pertuzumab in combination with trastuzumab and a taxane in first line treatment of patients with HER2- positive advanced (metastatic or locally recurr...
    Medical condition: Advanced breast cancer (metastatic or locally recurrent)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER-2 positive breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) FI (Completed) FR (Completed) ES (Completed) SI (Completed) GB (Completed) NL (Completed) DE (Completed) BE (Completed) HU (Completed) PT (Completed) GR (Completed) SE (Completed) IT (Completed) EE (Completed) LT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2021-005185-18 Sponsor Protocol Number: HEPA-CRV431-207 Start Date*: 2022-07-13
    Sponsor Name:Hepion Pharmaceuticals, Inc.
    Full Title: ASCEND-NASH: A PHASE 2B, RANDOMIZED, MULTI-CENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CRV431 IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS AND ADVAN...
    Medical condition: NONALCOHOLIC STEATOHEPATITIS AND ADVANCED LIVER FIBROSIS
    Disease: Version SOC Term Classification Code Term Level
    24.1 100000004871 10086370 NASH with fibrosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) HU (Prematurely Ended) IT (Prematurely Ended) ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-001082-17 Sponsor Protocol Number: DELA-01 Start Date*: 2019-08-19
    Sponsor Name:MENARINI RICERCHE S.p.A.
    Full Title: A randomized, observer-blinded, active-controlled, Phase IIIb study to compare IV / Oral delafloxacin fixed-dose monotherapy with best available treatments in a microbiologically enriched populatio...
    Medical condition: Acute Bacterial Skin and Skin Structure Infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10052891 Skin bacterial infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) GB (Prematurely Ended) HU (Prematurely Ended) LV (Prematurely Ended) SI (Prematurely Ended) ES (Prematurely Ended) AT (Prematurely Ended) PL (Prematurely Ended) EE (Prematurely Ended) BG (Prematurely Ended) HR (Completed) IT (Prematurely Ended) RO (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-001443-19 Sponsor Protocol Number: AC-058A200 Start Date*: 2008-11-26
    Sponsor Name:Actelion Pharmaceuticals Ltd
    Full Title: Multicenter, randomized, double-blind, placebo-controlled, Phase IIa study to evaluate the efficacy, safety, and tolerability of ACT-128800, an S1P1 receptor agonist, administered for 6 weeks to su...
    Medical condition: Moderate to severe chronic plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10037153 Psoriasis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) HU (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2015-000547-17 Sponsor Protocol Number: FPA008-002 Start Date*: 2015-11-18
    Sponsor Name:Five Prime Therapeutics, Inc.
    Full Title: A Phase 1/2 Study of FPA008, an anti-CSF1 Receptor Antibody, in Patients with Pigmented Villonodular Synovitis (PVNS)/ Diffuse Type Tenosynovial Giant Cell Tumor (dt-TGCT)
    Medical condition: Pigmented villonodular synovitis (PVNS)/Diffuse Type Tenosynovial Giant Cell Tumor (dt-TGCT)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10047413 Villonodular synovitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) FR (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2010-019970-33 Sponsor Protocol Number: CKRP203A2201 Start Date*: 2010-11-11
    Sponsor Name:Novartis Services AG
    Full Title: A multi-centre, double-blind, placebo controlled, parallel group, proof of concept study to evaluate the efficacy, safety and tolerability of KRP203 in subjects with moderately active refractory ul...
    Medical condition: Ulcerative colitis
    Disease: Version SOC Term Classification Code Term Level
    12.1 10045365 Ulcerative colitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) SE (Completed) BE (Completed) GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-004466-26 Sponsor Protocol Number: G1T28-04 Start Date*: 2017-07-10
    Sponsor Name:G1 Therapeutics
    Full Title: Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients with Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy
    Medical condition: Locally recurrent or metastatic Triple Negative Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) SI (Completed) HR (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2015-003242-22 Sponsor Protocol Number: BCX4161-303 Start Date*: 2015-12-17
    Sponsor Name:BioCryst Pharmaceuticals Inc
    Full Title: OPuS-4: An open-label study to evaluate the long-term safety of avoralstat in subjects with hereditary angioedema
    Medical condition: Hereditary Angioedema
    Disease: Version SOC Term Classification Code Term Level
    18.0 10010331 - Congenital, familial and genetic disorders 10019860 Hereditary angioedema PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) HU (Prematurely Ended) BE (Completed) FR (Prematurely Ended) GB (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-003219-26 Sponsor Protocol Number: MR-130A-01-TD-2001 Start Date*: 2023-01-10
    Sponsor Name:Mylan Pharmaceuticals, Inc
    Full Title: An open-label, phase II, dose-finding study of three dose strengths of MR-130A-01 contraceptive transdermal patch containing norelgestromin (NGMN) in healthy pre-menopausal women
    Medical condition: Investigation of ovulation inhibition for indication of contraception in healthy subjects
    Disease: Version SOC Term Classification Code Term Level
    22.0 10042613 - Surgical and medical procedures 10073728 Hormonal contraception PT
    Population Age: Adults Gender: Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-019825-32 Sponsor Protocol Number: CRAD001X2201 Start Date*: 2010-07-28
    Sponsor Name:NOVARTIS FARMA
    Full Title: An exploratory, open label, non-randomized, within-patient multiple dose-escalation safety, tolerability, PK and efficacy trial of RAD001 (everolimus) in patients with Lymphangioleiomyomatosis.
    Medical condition: Lymphangioleiomyomatosis
    Disease: Version SOC Term Classification Code Term Level
    12.1 10049459 Lymphangioleiomyomatosis LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2005-002261-37 Sponsor Protocol Number: OHB103755 Start Date*: 2005-08-01
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Flexible-Dose Study Evaluating the Efficacy, Safety, and Tolerability of Radafaxine Extended-Release (100-140mg/day) Com...
    Medical condition: Major Depressive Disorder
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) FI (Completed)
    Trial results: View results
    EudraCT Number: 2021-002176-39 Sponsor Protocol Number: V3002401 Start Date*: 2022-02-07
    Sponsor Name:Veru Inc.
    Full Title: ARTEST - A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Enobosarm Monotherapy Versus Active Control for the Treatment of AR+/ER+/HER2- Metastatic Breast Cancer in Patients with A...
    Medical condition: (AR+)/estrogen receptor positive(ER+)/human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-000106-41 Sponsor Protocol Number: CXA100750 Start Date*: 2004-09-07
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A study to investigate the effect of GW406381 on methotrexate pharmacokinetics in patients treated with methotrexate for rheumatoid arthritis
    Medical condition: The patients entering the trial have rheumatoid arthritis although treatment of the disease itself is not under investigation in this study.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2021-006779-41 Sponsor Protocol Number: CAR-GR Start Date*: 2022-10-26
    Sponsor Name:FUNDACIÓN FLS DE LUCHA CONTRA EL SIDA, LAS ENFERMEDADES INFECCIOSAS Y LA PROMOCIÓN DE LA SALUD Y LA CIENCIA
    Full Title: HIV-1 RNA suppression and drug concentrations in semen, cervicovaginal fluid and rectum in HIV-1 infected individuals receiving intramuscular long-acting cabotegravir plus rilpivirine (“CAR-GR Study)
    Medical condition: HIV infected individuals
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-005392-10 Sponsor Protocol Number: CBGG492A2204 Start Date*: 2009-03-31
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multi-centre, randomized, double-blind, parallel group, active and placebo controlled, Proof of Concept study in patients with acute migraine to assess the efficacy, safety and tolerability of si...
    Medical condition: Acute migraine
    Disease: Version SOC Term Classification Code Term Level
    9.1 10066635 Acute migraine LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2005-000813-36 Sponsor Protocol Number: HHT-CML/INTL/04.2 Start Date*: 2005-10-14
    Sponsor Name:STRAGEN France [...]
    1. STRAGEN France
    2. ChemGenex Pharmaceuticals Ltd.
    Full Title: A phase II, multicentre, single-arm, open-label study of subcutaneous homoharringtonine (HHT) alone in patients with accelerated phase chronic myeloid leukemia (CML) who are refractory to, or have ...
    Medical condition: Accelerated phase Chronic Myeloid Leukaemia (CML).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-004825-26 Sponsor Protocol Number: G200712 Start Date*: 2013-01-25
    Sponsor Name:GTx, Inc.
    Full Title: Phase II, open label study of the effect of GTx-758 as secondary hormonal therapy on serum PSA and serum free testosterone levels in men with castration resistant prostate cancer maintained on and...
    Medical condition: Assessments of serum total testosterone, serum free testosterone, serum SHGB and serum PSA concentrations will be made. Bone turnover markers and the incidence and frequency of hot flashes will be ...
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-001446-24 Sponsor Protocol Number: 178-CL-201 Start Date*: 2014-10-09
    Sponsor Name:Astellas Pharma Europe B.V.
    Full Title: A Phase 1, Single Dose, 4-Period Crossover Study to Assess the Bioavailability of an Mirabegron Oral Suspension Relative to the Mirabegron Prolonged Release Tablet and to Assess the Effect of Food ...
    Medical condition: No medical indication will be investigated as only healthy subjects will be included.
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004857 10059617 Overactive bladder LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-013665-26 Sponsor Protocol Number: CLDE225B2204 Start Date*: 2010-01-14
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A double-blind, randomized, vehicle-controlled Proof of Concept (PoC) study to evaluate the efficacy, safety, local tolerability, pharmacokinetics and pharmacodynamics of multiple topical administr...
    Medical condition: sporadic superficial skin basal cell carcinomas
    Disease: Version SOC Term Classification Code Term Level
    12.0 10042503 Superficial basal cell carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) AT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 14 11:44:27 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA